Broader equity markets experienced notable movement in the period surrounding this report. The Nasdaq 100 added approximately $3.5 trillion in market capitalisation over four consecutive trading sessions through mid-August 2026, attributed to strong corporate earnings and renewed interest in technology sectors [Brief - 2026-09-11]. This broader market context coincided with the generation of this report, which was triggered by material institutional position changes in CVS Health Corp.
As of 30 June 2026, CVS Health reported trailing twelve-month revenue of approximately $415.1 billion, representing year-over-year growth of 7.26% [SEC 10-Q - CVS - 2026-06-30]. Net income over the same period stood at approximately $4.9 billion, with a net margin of 1.18% and an operating margin of 1.997%. Gross margin was recorded at 7.06%. The company carried $11.3 billion in cash against total debt of $63.5 billion. The price-to-earnings ratio was 23.44, and market capitalisation was approximately $113.5 billion. EPS growth on a year-over-year basis was 188.75% [SEC 10-Q - CVS - 2026-06-30].
Four prominent institutional investors initiated new positions in CVS Health during the most recent 13F reporting period. Citadel (Ken Griffin), AQR Capital (Cliff Asness), Millennium (Izzy Englander), and Bridgewater (Ray Dalio) each opened new positions in the company [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026]. No insider transaction data was available for inclusion in this report.
The prevailing macro environment as of the report generation date shows the 10-year US Treasury yield at 4.94% and the 2-year yield at 4.67%, producing a normal yield curve spread of 27 basis points [FRED DGS10] [FRED DGS2]. This rate environment is relevant context for a company carrying $63.5 billion in total debt, as borrowing costs and refinancing conditions reflect broader fixed-income market dynamics.